Anlon Healthcare Limited has reported impressive financial results for the quarter ended September 30, 2025, demonstrating significant growth across key metrics.

Financial Highlights

The company's Q2 FY26 performance shows substantial year-over-year improvements:

• Total income rose 116% to INR 52.32 crore
• Profit after tax (PAT) increased nearly 4 times to INR 9.32 crore
• Revenue from operations grew 37.8% to INR 33.29 crore, up from INR 24.17 crore in the previous year's quarter

Half-Year Performance

For the half-year period:

• Revenue reached INR 61.99 crore, up from INR 53.56 crore in the previous period
• Profit after tax increased to INR 12.86 crore, compared to INR 6.36 crore previously

Company Overview

Anlon Healthcare Limited, a pharmaceutical manufacturer specializing in Active Pharmaceutical Ingredients (APIs) and drug intermediates, has been listed on the stock exchanges since September 3, 2025.

Financial Position

• Total assets increased to INR 287.52 crore from INR 188.48 crore as of March 31, 2025
• The company has utilized INR 82.45 crore from its IPO proceeds of INR 121.03 crore, with INR 38.58 crore remaining unutilized

Future Plans

Anlon Healthcare is planning expansion to meet growing demand:

• A 700 metric ton greenfield expansion is in progress
• The company is exploring inorganic acquisitions to enhance its capabilities
• Anlon Healthcare aims to achieve a 30% revenue CAGR over the next three years, with a focus on regulated markets

The company's quarterly results are attributed to strong operating leverage and an improved business mix. Anlon Healthcare's Q2 performance reflects its position in the market and its ability to capitalize on growth opportunities. The increase in revenue and profit demonstrates the company's strategies and the market demand for its products.

Anlon Healthcare Limited has seen a significant reduction in stake by Neomile Asset Managers Private Limited through a series of open market transactions. The sales, which took place between November 3-4, 2025, have altered the ownership structure of the healthcare company.

Key Details of the Transaction

Impact on Shareholding

The open market sale has resulted in a notable change in Neomile Asset Managers' position in Anlon Healthcare. Their holding has decreased from 10.40% to 7.62% of the company's total share capital, representing a reduction of 2.78 percentage points.

Transaction Participants

Neomile Growth Fund-Series I was acting in concert with Neomile Corporate Advisory Limited as the seller in these transactions. This coordinated action suggests a strategic move by the Neomile group to adjust their investment in Anlon Healthcare.

Company Listing

Anlon Healthcare maintains its presence on both the National Stock Exchange and Bombay Stock Exchange, providing investors with multiple trading venues for the company's shares.

The reduction in Neomile Asset Managers' stake may attract attention from market participants. However, the immediate impact on Anlon Healthcare's operations or market performance remains to be seen.